3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Status
Completed
9
Active not recruiting
9
Withdrawn
4
Terminated
4
Recruiting
2
Not yet recruiting
1
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Genitourinary
2
Conditions
Carcinoma, Renal Cell
3
Urinary Bladder Neoplasms
2
Triple Negative Breast Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Prostatic Neoplasms
2
Neoplasms
2
Head and Neck Neoplasms
2
Carcinoma, Transitional Cell
2
Breast Neoplasms
2
Stomach Neoplasms
1
Solid Tumor
1
Small Cell Lung Carcinoma
1
Penile Squamous Cell Carcinoma (PSCC)
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasm, Residual
1
Neoplasm Metastasis
1
Metastatic Urothelial Cancer
1
Melanoma
1
Lymphatic Metastasis
1
Gestational Trophoblastic Neoplasias (GTN)
1
Endometrial Neoplasms
1
Diabetes Mellitus, Insulin-Dependent, 10
1
Carcinoma, Squamous Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Merkel Cell
1
Advanced Solid Tumor
1
Interventions
pembrolizumab
21
enfortumab vedotin
13
Gemcitabine
12
Nivolumab
8
Cisplatin
8
Carboplatin
8
Magnetic Resonance Spectroscopy
6
Specimen Handling
5
Docetaxel
5
toripalimab
4
sacituzumab govitecan
4
Paclitaxel
4
Ipilimumab
4
atezolizumab
3
Mitomycin
3
Fluorouracil
3
disitamab vedotin
2
cabozantinib
2
avelumab
2
Radiosurgery
2
Platinum
2
Injections
2
Immunotherapy
2
Fluorodeoxyglucose F18
2
Cyclophosphamide
2
Biopsy
2
zanidatamab
1
tremelimumab
1
tamibarotene
1
talazoparib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Recruiting
×
Carcinoma, Transitional Cell
×
avelumab
×
Clear all
NCT04678362
2025-09-22
TALASUR
Centre Francois Baclesse
Phase 2
Recruiting
50 enrolled
NCT05600127
2023-09-08
CHASIT
Erasmus Medical Center
Phase 2
Recruiting
64 enrolled